Sentences with phrase «in heparin»

To establish your cat's FCoV antibody titre get your veterinary surgeon to send 0.5 - 1.0 ml blood in a heparin tube to the Companion Animal Diagnostics, University of Glasgow Veterinary School, Bearsden, Glasgow, G61 1QH, United Kingdom.

To establish your kittens's FCoV antibody titre get your veterinary surgeon to send 0.5 - 1.0 ml blood in a heparin tube to the Companion Animal Diagnostics, University of Glasgow Veterinary School, Bearsden, Glasgow, G61 1QH, United Kingdom.

Polyphosphate / platelet factor 4 complexes can mediate heparin - independent platelet activation in heparin - induced thrombocytopenia.

Not exact matches

Examples from the last few years include the subprime mortgage crisis; the failure of the Peanut Corporation of America; the 2007 pet food scandal; lead paint on children's toys in 2007; melamine - laced Chinese milk products; contaminants in the drug Heparin; and dioxin - contaminated Irish pork.

SPL is the world's largest independent provider of heparin, an anticoagulant, and is a leader in the production of pancreatin, used to treat Cystic Fibrosis and a variety of digestive disorders.

Examples are gentamicin (and other drugs in this family of antibiotics), heparin, interferon, local anesthetics, omperazole.

With an allergic reaction, there is a release of mast cells, which contain heparin and histamine and then follows by an increase in IgE.

Yes the home group will contain some higher risk moms (some VBAC, some breech, some GDM) but it won't contain the full spectrum of high risk that the hospital gets: Women with clotting disorders on heparin, maternal heart disease, moms addicted to crack, moms with HIV, 12 and 13 year olds, women who walk in off the streets in labor with no prenatal care, women with sickle cell and cystic fibrosis and type 1 diabetes, babies with severe anomalies.

However, the doctors wouldn't risk putting another needle in my back now that the original had already been removed and I was back on heparin injections.

I had no epidural and no IV fluids but I allowed a heparin lock just in case.

GTC recognized the need to demonstrate on its own the potential for the technology and, in the late 1990s, began a clinical trial of human antithrombin for patients undergoing bypass surgery who develop resistance to the anticoagulant drug heparin.

«However, our study showed that in the real world over a third of the patients with STEMI undergoing transradial PCI who receive heparin and about a fifth of patients who receive bivalirudin also receive GPIIb / IIIa inhibitors.»

In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study in JACC: Cardiovascular InterventionIn patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study in JACC: Cardiovascular Interventionin the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study in JACC: Cardiovascular Interventionin JACC: Cardiovascular Interventions.

The authors suggested that a randomized trial in patients treated exclusively via transradial primary PCI and anticoagulated with bivalirudin versus heparin as well as a cost - effectiveness analysis comparing heparin versus bivalirudin would help practitioners and hospitals make better decisions regarding anticoagulation in these patients.

«Our sensitivity analysis provides some insights into direct comparisons of bivalirudin and heparin when GPIIb / IIIa inhibitors are forced out of the equation and suggests that in the direct comparison bivalirudin may have superior outcomes,» Jovin said.

Previous multicenter trials, such as HORIZONS - AMI and EUROMAX, have demonstrated superiority of bivalirudin to heparin plus glycoprotein IIb / IIIa inhibitors (GPI), but a recent single center trial, HEAT - PPCI, demonstrated the superiority of heparin monotherapy over bivalirudin alone, with concern for an increased rate of stent thrombosis observed in bivalirudin - treated patients.

After 30 days, NACE occurred in 65 (8.8 %) bivalirudin - treated patients compared to 96 (13.2 %) heparin - treated patients (relative risk [RR]: 0.67, 95 % CI: 0.50 - 0.90; difference: -4.3 %, 95 % CI: -7.5 % ---1.1 %; P = 0.008); and 124 (17.0 %) heparin plus tirofiban - treated patients (RR for bivalirudin vs. heparin plus tirofiban: 0.52, 95 % CI: 0.39 - 0.69; difference: -8.1 %, 95 % CI: -11.6 % ---4.7 %; P < 0.001).

«By reducing bleeding with comparable rates of MACCE and stent thrombosis, bivalirudin significantly improved overall 30 - day and one year outcomes, compared with both heparin alone and heparin plus tirofiban in patients with AMI undergoing primary PCI,» said Gregg W. Stone, MD, the study's senior author.

Data from the BRIGHT trial recently published in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).

The tissue clumps are nurtured in new broth infused with growth enhancers: a gelatin - like matrix of support proteins called Matrigel, B27 vitamin supplement, heparin and the growth promoter LIF.

At one year, bivalirudin resulted in sustained reductions in NACE compared to heparin (12.8 % vs. 16.5 %, RR: 0.78, 95 % CI: 0.61 - 0.99; difference: -3.7 %, 95 % CI: -7.3 % ---0.1 %; p = 0.048) and compared to heparin plus tirofiban (12.8 % vs. 20.5 %, RR: 0.62, 95 % CI: 0.49 - 0.79; difference: -7.8 %, 95 % CI: -11.6 % ---4.0 %; p < 0.001), due to lower rates of bleeding.

A phase 2 trial showed a reduction in the combined outcome of death or myocardial infarction (heart attack) in patients treated with otamixaban compared with unfractionated heparin (UFH) plus eptifibatide (an antiplatelet drug) and showed similar bleeding rates with otamixaban at midrange doses.

As is common in major operations, heparin, a blood - thinning agent, was injected to prevent clotting; the drug must be removed after surgery to allow the patient's wounds to heal.

Additionally, the gentamicin / citrate solution was associated with a 73 percent reduction in bloodstream infections compared to the heparin treatment.

The most alarming report involved contaminated batches of the blood thinner heparin, which caused at least three deaths and is under suspicion in dozens of others.

What's more, the women in both the heparin and control groups also received injections of the drug for 42 days after birth, potentially helping to protect them against blood clots that may manifest themselves at that point, but possibly diluting the results — making it appear that heparin was not as effective as it may have been.

«We had systems that bound DNA, and they can all, in principle, be used to bind heparin as well..., so we could start pretty much instantly,» he says.

But to be fair, much of the concern is rooted in some scary generic drug scandals, in which toxic substances made it into a medication that was produced overseas, such as occurred with heparin in 2008.

Now scientists have assembled a synthetic abridged form of heparin that, in animals, appears to work better than the real thing.

With a molecular tether in between six uncharged sugars, the synthetic compound is only 17 sugars long, compared to heparin's hundreds.

But heparin also attaches to a substance called PF4, which in certain patients can trigger new clots.

In today's Nature, scientists from the pharmaceutical company Sanofi in Toulouse, France, report that they have stitched together a heparin substitutIn today's Nature, scientists from the pharmaceutical company Sanofi in Toulouse, France, report that they have stitched together a heparin substitutin Toulouse, France, report that they have stitched together a heparin substitute.

The other compound is modelled on heparin — a sulphated polysaccharide similar to starch — which is found in some blood cells.

Patients in the control group were given the widely used anticoagulant unfractionated heparin, as well as glycoprotein IIb / IIIa inhibitors, another class of anticoagulants, at the physician's discretion.

«I believe the study shows bivalirudin can provide additional benefits to patients as compared to unfractionated heparin in current medical practice.»

In a key departure from its predecessors, the MATRIX trial allowed interventional cardiologists to decide whether to give glycoprotein IIb / IIIa inhibitors as a complement to unfractionated heparin in control patients, whereas previous studies either required or forbade the use of these drugIn a key departure from its predecessors, the MATRIX trial allowed interventional cardiologists to decide whether to give glycoprotein IIb / IIIa inhibitors as a complement to unfractionated heparin in control patients, whereas previous studies either required or forbade the use of these drugin control patients, whereas previous studies either required or forbade the use of these drugs.

On arrival, islets were immediately placed in CMRL 1066 (Cellgro; Corning) enriched medium, supplemented with 2 mM l - glutamine (Cellgro CN - 25 -005-CI; Corning), 1 mM sodium pyruvate, (Cellgro CN -25-000-CI; Corning), 10 mM Hepes - free acid, (Cellgro CN - 25 -060-CI; Corning), 10 U / ml heparin (Hospira RL - 4311; Pfizer), and 10 mM nicotinamide, (CN N0636; Sigma - Aldrich) at 24 °C with 5 % CO2 for 7 d to stabilize the islets before starting the experiments.

The fact that four of the drugs used in the tests — heparin, cytochalasin D, ethyl - isopropyl amiloride and choloroquine — are already approved by the Food and Drug Administration for other uses suggests that they may also be useful as chemotherapeutic agents, Nagrath said.

Developing a three dimensional in vitro cell culture model for studying breast and prostate cancer using starPEG - heparin hydrogels.

Monocyte - bound PF4 in the pathogenesis of heparin - induced thrombocytopenia.

Relative antithrombotic and antihemostatic effects of protein C activator versus low - molecular - weight heparin in primates.

Andrea Zieris (Werner, LG)-- «Modulation of growth factor functionality through immobilization in starPEG - heparin networks» (2012)

A comparable reduction in plasma TG levels occurred after heparin injection of mice treated with ApoC - III ASO (Figure 7A).

Administration of tamoxifen to LPL - deficient mice resulted in a significant reduction in Lpl mRNA expression in liver, muscle, heart, and adipose tissue (Supplemental Figure 5A) and in LPL activity in plasma (after i.v. heparin administration), muscle, heart, and adipose tissue (Supplemental Figure 5B).

Broad heparin - binding haemagglutinin - specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination.

(A and B) Plasma TGs were measured before and after heparin injection in WT, Ldlr — / — Ndst1fl / fl Alb - Cre +, and Ldlr — / — Lrp1fl / fl Alb - Cre + mice treated for 4 weeks with control or ApoC - III ASO (A) after an overnight fast or (B) 3 hours after a fat challenge.

And although the heparin - induced lipolysis experiments suggest that ApoC - III depletion does not affect LPL activity, we can not fully exclude the possibility that ApoC - III depletion might differentially affect LPL activity in different tissues.

A clinical study of anticoagulants in acute myocardial infarction with particular reference to early heparin therapy.

In future oral heparin studies, scientists could investigate changes in dogs» blood vessels by examining these tissues after giving oral heparin doses to the animalIn future oral heparin studies, scientists could investigate changes in dogs» blood vessels by examining these tissues after giving oral heparin doses to the animalin dogs» blood vessels by examining these tissues after giving oral heparin doses to the animals.

Heparin (75 - 150IU / kg TID) may be potentially useful in ameliorating DIC, promoting adequate microcirculation in the pancreas and clearing lipemic serum.